United States Hypertriglyceridemia Treatment Market 2031 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Global Hypertriglyceridemia Treatment Market is expected to reach at a high CAGR during the forecast period 2023-2030.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/hypertriglyceridemia-treatment-market?sb

Key Development:

United States: Recent Hypertriglyceridemia Treatment Developments

✅ In December 2025, the U.S. FDA granted Breakthrough Therapy designation to plozasiran as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (SHTG), expediting development and review based on strong preliminary clinical evidence.

✅ In December 2025, the U.S. FDA also granted Breakthrough Therapy designation to olezarsen for treating adults with severe hypertriglyceridemia, recognizing its potential to substantially improve triglyceride reduction outcomes.

✅ In November 2025, pivotal Phase 3 CORE and CORE2 study results for olezarsen demonstrated up to a 72 % placebo‐adjusted reduction in fasting triglycerides and a significant reduction in acute pancreatitis events in severe hypertriglyceridemia patients, presented at AHA 2025.

✅ In November 2025, plozasiran (Redemplo) received FDA approval for treating familial chylomicronemia syndrome (FCS), marking a new therapeutic option to reduce triglyceride levels in patients with this severe lipid disorder

✅ In November 2025, pivotal data from the AHA 2025 Scientific Sessions showed olezarsen significantly reduced triglycerides and acute pancreatitis risk in severe hypertriglyceridemia, reinforcing its potential broader clinical impact.

✅ In November 2025, detailed data showed olezarsen's treatment significantly lowered triglyceride levels and reduced acute pancreatitis risk in patients with severe hypertriglyceridemia across CORE‐TIMI 72a and CORE2‐TIMI 72b trials, reinforcing its therapeutic promise.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=hypertriglyceridemia-treatment-market

Japan: Recent Hypertriglyceridemia Treatment Developments

✅ In November 2025, Otsuka Pharmaceutical launched NEXLETOL® (bempedoic acid) in Japan for the treatment of hypercholesterolemia and familial hypercholesterolemia, expanding options for lipid management even though it primarily targets LDL‐cholesterol rather than triglycerides directly.

✅ In December 2025, recent clinical presentations and publications highlighted ongoing interest in ApoC‐III and PPARα‐modulating agents as potential future treatments for hypertriglyceridemia, reflecting Japan's research engagement with next‐generation lipid‐lowering therapies.

✅ In the past 3 months, Japanese research continues to emphasize pemafibrate extended‐release formulations showing convenient once‐daily triglyceride lowering and potential adherence benefits, supporting broader dyslipidemia care strategies.

✅ In 2025, Japanese investigators are advancing siRNA and gene‐targeted strategies that could translate into new hypertriglyceridemia therapies, with preclinical models showing promising mechanistic insights for future drug discovery.

✅ In recent months, ongoing OM3‐FFA investigational studies in Japanese dyslipidemia patients reaffirm the role of omega‐3 fatty acid combinations in triglyceride lowering, with implications for clinical practice and future therapeutic refinements.

✅ In 2025, a new Triple Agonist therapy (DR10624) tested in severe hypertriglyceridemia showed promising phase II results with triglyceride and liver‐fat reduction at a major clinical meeting, signaling a potential upcoming therapeutic option.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/hypertriglyceridemia-treatment-market?sb

Key Players:

=> Hikma Pharmaceuticals PLC, Woodward Pharma Services LLC, AstraZeneca, Bristol-Myers Squibb Company, Bayer AG, Ionis Pharmaceuticals Inc., Mylan N.V., Accord Healthcare, Sun Pharmaceutical Industries Limited, and Amryt Pharma plc, among others.

Key Segments:

By Drug Class

Statins lead the market with 45% share, extensively prescribed for hypercholesterolemia and cardiovascular disease prevention. Fibrates account for 20%, mainly used for managing high triglyceride levels. Omega-3 Fatty Acids hold 15%, driven by nutraceutical applications and adjunct therapy. Others contribute 20%, including bile acid sequestrants, cholesterol absorption inhibitors, and combination therapies.

By Distribution Channel

Retail Pharmacies dominate with 40% share, offering wide accessibility and convenience for chronic therapy. Hospital Pharmacies hold 35%, primarily serving in-patients and long-term treatment needs. Online Pharmacies account for 25%, growing due to e-commerce adoption and home delivery services.

By Region

North America - 35% Share
High prevalence of cardiovascular diseases, advanced healthcare infrastructure, and strong insurance coverage drive market demand.

Europe - 30% Share
Aging population, preventive healthcare initiatives, and reimbursement policies boost statin and fibrate consumption.

Asia Pacific - 20% Share
Rapid urbanization, rising incidence of cardiovascular disorders, and expanding healthcare access support growth.

Latin America - 8% Share
Moderate growth supported by improving healthcare infrastructure and government programs.

Middle East & Africa - 7% Share
Opportunities driven by growing awareness of cardiovascular health and gradual expansion of pharmacies and healthcare services.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.